Aquestive Therapeutics (AQST) COO reports equity grants and tax sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Aquestive Therapeutics, Inc. Chief Operating Officer Cassie Jung reported a combination of equity grants and a mandated share sale. She received 80,000 shares of restricted common stock and a non-qualified stock option for 42,500 shares at an exercise price of $4.29 per share, vesting over three annual installments. To cover tax withholding from restricted stock unit vesting, she sold 45,791 shares of common stock at a weighted average price of $4.173 per share in transactions described as required "sell to cover" trades rather than discretionary sales. After these moves, she directly holds 274,980 common shares and indirectly holds 2,000 shares through her spouse, along with the newly granted option expiring on March 9, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 45,791 shares ($191,086)
Net Sell
4 txns
Insider
Jung Cassie
Role
Chief Operating Officer
Sold
45,791 shs ($191K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 45,791 | $4.173 | $191K |
| Grant/Award | Non-Qualified Stock Option (right to buy) | 42,500 | $0.00 | -- |
| Grant/Award | Common Stock | 80,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 274,980 shares (Direct);
Non-Qualified Stock Option (right to buy) — 42,500 shares (Direct);
Common Stock — 2,000 shares (Indirect, by spouse)
Footnotes (1)
- The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
FAQ
What insider transactions did Aquestive Therapeutics (AQST) COO Cassie Jung report?
Cassie Jung reported equity grants and a tax-related sale. She received 80,000 restricted common shares and a stock option for 42,500 shares, then sold 45,791 shares to cover tax withholding tied to restricted stock unit vesting.
What new equity awards did the Aquestive Therapeutics (AQST) COO receive?
Cassie Jung received two main awards: 80,000 shares of restricted common stock and a non-qualified stock option for 42,500 underlying shares at a $4.29 exercise price. Both the restricted stock and options vest over three annual installments with a 25%, 25%, 50% schedule.
What are Cassie Jung’s holdings in Aquestive Therapeutics (AQST) after these transactions?
After the reported transactions, Cassie Jung directly holds 274,980 shares of Aquestive Therapeutics common stock and indirectly holds 2,000 shares through her spouse. She also holds a non-qualified stock option covering 42,500 shares of common stock expiring March 9, 2036.